- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01929226
Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers
A Double-Blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of ETI-204 in Adult Volunteers
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
A double-blind, randomized, placebo-controlled study of a single IV dose of 16 mg/kg ETI-204 in adult volunteers (210 subjects ETI-204; 70 subjects placebo).
The total duration of the study for each subject will be approximately 100 days divided as follows:
Screening: Days -28 to -2; In-unit Phase: Day -1, Day 1, and Day 2; Out-of-unit Visits: Day 8 (±2 days); Day 15 (±3 days); Day 29 (±3 days); Day 43 (±3 days); Final Visit: Day 71 (±4 days).
Following completion of a screening visit subjects who qualify for entry into the study will be randomized to receive either ETI-204 or matching placebo on Day 1 in a 3:1 ratio. Subjects will be discharged from the clinic on Day 2 following completion of study assessments and will return for five additional visits on Days 8, 15, 29, 43 and 71.
The first 12 subjects will be dosed in groups of no more than 4 subjects/day. A blinded safety review of the available clinical and laboratory AE data up to and including Day 2 will be completed for the first 12 subjects before any additional subjects are dosed. This review will be conducted by the Investigator in conjunction with the Clinical Trial Steering Committee. If the outcome of this review is satisfactory, dosing of additional subjects will be permitted to continue and subjects may be dosed in group sizes larger than 4.
After Amendment 1, premedication with 50 mg oral diphenhydramine approximately 30 minutes prior to the start of study drug infusion was required.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75247
- Covance Clinical Research Inc.
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Females or males ≥ 18 years of age
- All females, regardless of childbearing potential, must have a negative serum beta human chorionic gonadotropin (β-hCG) pregnancy test at Screening and Day -1
- Females of childbearing potential (i.e., not postmenopausal or surgically sterile) must agree to practice abstinence or to use a medically accepted method of contraception from the time of Screening through 30 days after final study visit. Acceptable methods of contraception include diaphragm with spermicide; sponge with spermicide; condom with spermicide; or intrauterine device with condom or spermicide. The following contraceptive methods are acceptable only when used with a condom and spermicide: birth control pills, birth control patches, vaginal ring, hormone under the skin, or hormone injections
- Postmenopausal females, defined as females who have had amenorrhea for at least 12 months either naturally or following cessation of all exogenous hormonal treatments and have a follicle stimulating hormone (FSH) level of > 40 mIU/mL at Screening
- Females who have undergone surgical sterilization, including hysterectomy, bilateral oophorectomy, bilateral salpingectomy, tubal ligation, or tubal essure
- Males must agree to practice abstinence or use a condom with spermicide and refrain from sperm donation during the study and for 30 days after the final study visit
- Provide written informed consent
- Willing to comply with study restrictions
Exclusion Criteria:
- Pregnant or lactating woman
- Clinically significant comorbidity that would interfere with completion of the study procedures or objectives, or compromise the subject's safety
- Seated systolic blood pressure (BP) ≥ 150 mmHg or ≤ 90 mmHg or diastolic BP ≥ 95 mmHg
- Use of H1 receptor antagonists (i.e. antihistamines) within 5 days prior to Day 1
- Evidence of drug or alcohol abuse as determined by the Investigator within 6 months of Day 1
- Positive test result for drugs of abuse (with the exception of medically prescribed drugs) at Screening or on Day -1
- Positive test for alcohol at Screening; exclusion is subject to the Investigator's discretion; subjects who test positive for alcohol at Day -1 are excluded from the study
- Treatment with an investigational agent within 30 days of Day 1 or within five half-lives of the investigational agent at Day 1 (whichever is longer)
- Congenital or acquired immunodeficiency syndrome
- Prior solid organ or bone marrow transplant
- Positive test for Hepatitis B (surface antigen), Hepatitis C, or human immunodeficiency virus (HIV) at Screening
- History of prior treatment for anthrax exposure or prior anthrax infection
- Prior immunization with any approved or investigational anthrax vaccine or prior treatment with an investigational anthrax treatment (i.e., ETI-204, raxibacumab, or anthrax immune globulin)
- Military personnel deployed in 1990 or after, unless the subject can provide documentation demonstrating they have not previously received any approved or investigational anthrax vaccine
- Use of systemic steroids, immunosuppressive agents, anticoagulants, or anti-arrhythmics within 1 year prior to Day 1. A single short course (i.e., less than 14 days) of systemic steroid therapy is allowed provided it concluded more than 6 months prior to Day 1
- Donation or loss of > 500 mL of blood within 30 days or plasma within 7 days of Day 1
- Prior stroke, epilepsy, relapsing or degenerative central nervous system disease, or relapsing or degenerative ocular disease
- Myocardial infarction or acute coronary syndrome in the past 5 years, active angina pectoris, or heart failure (New York Heart Association scale > 1)
- History of chronic liver disease
- Calculated creatinine clearance (CrCl) of < 30 mL/min using the Cockcroft-Gault equation
- Any clinically significant abnormality, in the Investigator's opinion, on electrocardiogram (ECG) or clinical laboratory tests (hematology, clinical chemistry, or urinalysis) at Screening; Out of range results may be repeated to confirm.
- History of allergic or hypersensitivity reactions to other therapeutic antibodies or immunoglobulins
- History of any malignant neoplasm within the last 5 years, with the exception of adequately treated localized or in situ non-melanoma carcinoma of the skin (i.e., basal cell carcinoma) or the cervix
- Subjects who, in the opinion of the Investigator, are not suitable candidates for enrollment or who may not comply with the requirements of the study
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: ETI-204
A single intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1
|
Monoclonal Antibody
|
Comparador de Placebo: Placebo for ETI-204
A single intravenous dose of ETI-204-placebo infused over 90 minutes on Day 1
|
Placebo para ETI-204
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Number of Participants Who Experienced Adverse Events
Prazo: Up to 71 days or 101 days (30 days after the final study visit) for subjects with ongoing adverse events at the final study visit, for each group.
|
Safety was assessed for all subjects in the safety population by collecting and monitoring vital signs, clinical laboratory tests, ECGs, physical examinations, skin assessments, infusion site assessments, and adverse events.
|
Up to 71 days or 101 days (30 days after the final study visit) for subjects with ongoing adverse events at the final study visit, for each group.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Maximum Observed Plasma Concentration of ETI-204 (Cmax)
Prazo: On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.
|
On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Time to Maximum Observed Plasma Concentration of ETI-204 (Tmax)
Prazo: On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.
|
On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUC0-last)
Prazo: On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.
|
On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf)
Prazo: On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.
|
On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Terminal Half-life (t1/2)
Prazo: On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.
|
On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Systemic Clearance (CL)
Prazo: On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.
|
On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Volume of Distribution (Vd)
Prazo: On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.
|
On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Volume of Distribution at Steady State (Vss)
Prazo: On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Blood samples were obtained and serum concentrations were determined using a validated enzyme-linked immunosorbent assay method with an assay range of 100 ng/mL to 5000 ng/mL.
|
On Day 1, prior to the start of infusion, at the end of infusion, and 3 and 8 hours after the start of infusion and on Days 2, 8, 15, 29, 43, and 71.
|
Number of Participants With Anti-ETI-204 Antibodies
Prazo: On Day 1 prior to the start of infusion and on Days 8, 43, and 71.
|
Serum anti-ETI-204 antibody titers were determined for all subjects in the safety population.
Blood samples were collected and serum samples were assayed at an initial dilution of 1:10.
Samples that were positive at the 1:10 dilution were serially diluted 1:2 and assayed until a negative result was attained.
The titer of the most dilute sample yielding a positive result was recorded as the titer for that time point.
Immunogenicity was measured by the number of participants in each study arm with anti-ETI-204 antibody values post-treatment ≥ 4-times higher than baseline at Day 8, 43 or 71, or if the titer was negative at baseline, the post-treatment sample(s) required a titer of at least 1:20 for it to be considered positive.
|
On Day 1 prior to the start of infusion and on Days 8, 43, and 71.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Alex King, MD, Covance
- Investigador principal: Lori Sieboldt, MD, Covance Clinical Research - Evansville, IN
- Investigador principal: Debra Mandarino, MD, Covance Research, Madison, WI
- Investigador principal: H. Frank Farmer, PhD, MD, Covance Research - Daytona Beach, Fl
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- AH104
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em ETI-204
-
Elusys TherapeuticsConcluídoVoluntários SaudáveisEstados Unidos
-
Elusys TherapeuticsConcluídoAntraz por InalaçãoEstados Unidos
-
University of AarhusRecrutamentoFibrose Cística (FC) | Mutação do gene CFTRDinamarca
-
Wyeth is now a wholly owned subsidiary of PfizerRescindidoDiabetes MellitusChina, Estados Unidos, Canadá, México, Federação Russa, Croácia, Reino Unido, Argentina, Austrália, Índia, África do Sul, Grécia, Ucrânia, Romênia, Itália, Hong Kong, Ex-Sérvia e Montenegro, Brasil
-
ACADIA Pharmaceuticals Inc.Ainda não está recrutandoDoença de Alzheimer PsicoseEstados Unidos
-
Wyeth is now a wholly owned subsidiary of PfizerConcluídoDiabetes MellitusJapão
-
Elusys TherapeuticsConcluídoAntraz por InalaçãoEstados Unidos
-
TScan Therapeutics, Inc.RecrutamentoMelanoma | Câncer cervical | Câncer de Cabeça e Pescoço | Malignidade Relacionada ao HPV | Cancro do ovário | Carcinoma Relacionado ao HPV | Carcinoma Cervical Relacionado ao HPV | Carcinoma de Células Escamosas de Orofaringe Positivo para HPV | Carcinoma de Células Não Pequenas | HPV - Infecção Anogenital... e outras condiçõesEstados Unidos
-
University of Medicine and Pharmacy at Ho Chi Minh...ConcluídoDoença de Graves | Imunoglobulina | Distúrbio de Anticorpos AntitireoidianosVietnã
-
National Taiwan University HospitalDesconhecidoManejo pré-hospitalar das vias aéreas em pacientes com parada cardíaca